NCT04611724 - A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

September 30, 2024

Conditions

Urachal Cancer

Interventions

DRUG

FOLFIRINOX

oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours

Trial Locations (1)

Unknown

RECRUITING

Asan Medical Center, Seoul